Literature DB >> 15193722

Identification and quantitation of extractables from cellulose acetate butyrate (CAB) and estimation of their in vivo exposure levels.

Decheng Ma1, Walter R Wasylaschuk, Christopher Beasley, Zhongxi Zack Zhao, Paul A Harmon, John M Ballard, Steven M Pitzenberger, Sandor L Varga, Robert A Reed.   

Abstract

The purpose of this study was to qualitatively and quantitatively determine potential cellulose acetate butyrate (CAB) extractables in a way to meaningfully predict the in vivo exposure resulting from clinical administration. Extractions of CAB-381-20 were performed in several solvent systems, consistently resulting in the detection of three extractables. The extractables have been identified as acetic acid, butyric acid, and E-2-ethyl-2-hexenoic acid (E-EHA) by LC/UV, LC/MS and NMR. Extraction studies of CAB powders in acetonitrile/phosphate buffer demonstrated quantitative extraction in 1 h for acetic acid (approximately 150 microg/g), butyric acid (approximately 200 microg/g), and EHA (approximately 20 microg/g). Subsequently, extraction studies for CAB powders and coated tablets in USP simulated gastric and intestinal fluids were performed to evaluate potential in vivo exposure. Similarly, acetic and butyric acids were quantitatively extracted from CAB-381-20 powder after 24 h exposure in both USP simulated fluids. The amounts of EHA extracted from CAB powder after 24 h were determined to be 2 and 16 microg/g in USP simulated gastric and intestinal fluids, respectively. After 24 h exposure in USP simulated fluids, the maximum amount of EHA extracted corresponds to < 0.3 microg of EHA per tablet. Pepsin and pancreatin in USP simulated fluids had no effect on EHA extraction and quantitation. Copyright 2004 Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15193722     DOI: 10.1016/j.jpba.2004.03.004

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  2 in total

Review 1.  Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility.

Authors:  Yongmei Wu; Jaquan Levons; Ajit S Narang; Krishnaswamy Raghavan; Venkatramana M Rao
Journal:  AAPS PharmSciTech       Date:  2011-09-27       Impact factor: 3.246

Review 2.  Magnetic hydroxyapatite: a promising multifunctional platform for nanomedicine application.

Authors:  Sudip Mondal; Panchanathan Manivasagan; Subramaniyan Bharathiraja; Madhappan Santha Moorthy; Hye Hyun Kim; Hansu Seo; Kang Dae Lee; Junghwan Oh
Journal:  Int J Nanomedicine       Date:  2017-11-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.